| Literature DB >> 34783606 |
Elke Anklam1, Martin Iain Bahl2, Robert Ball3, Richard D Beger3, Jonathan Cohen3, Suzanne Fitzpatrick3, Philippe Girard4, Blanka Halamoda-Kenzaoui1, Denise Hinton3, Akihiko Hirose5, Arnd Hoeveler1, Masamitsu Honma5, Marta Hugas6, Seichi Ishida5, George En Kass6, Hajime Kojima5, Ira Krefting3, Serguei Liachenko3, Yan Liu7, Shane Masters3, Uwe Marx8, Timothy McCarthy9, Tim Mercer10, Anil Patri3, Carmen Pelaez11, Munir Pirmohamed12, Stefan Platz13, Alexandre Js Ribeiro3, Joseph V Rodricks14, Ivan Rusyn15, Reza M Salek16, Reinhilde Schoonjans6, Primal Silva17, Clive N Svendsen18, Susan Sumner19, Kyung Sung3, Danilo Tagle20, Li Tong21, Weida Tong3, Janny van den Eijnden-van-Raaij22, Neil Vary17, Tao Wang23, John Waterton24, May Wang21, Hairuo Wen25, David Wishart26, Yinyin Yuan27, William Slikker3.
Abstract
There is an evolution and increasing need for the utilization of emerging cellular, molecular and in silico technologies and novel approaches for safety assessment of food, drugs, and personal care products. Convergence of these emerging technologies is also enabling rapid advances and approaches that may impact regulatory decisions and approvals. Although the development of emerging technologies may allow rapid advances in regulatory decision making, there is concern that these new technologies have not been thoroughly evaluated to determine if they are ready for regulatory application, singularly or in combinations. The magnitude of these combined technical advances may outpace the ability to assess fit for purpose and to allow routine application of these new methods for regulatory purposes. There is a need to develop strategies to evaluate the new technologies to determine which ones are ready for regulatory use. The opportunity to apply these potentially faster, more accurate, and cost-effective approaches remains an important goal to facilitate their incorporation into regulatory use. However, without a clear strategy to evaluate emerging technologies rapidly and appropriately, the value of these efforts may go unrecognized or may take longer. It is important for the regulatory science field to keep up with the research in these technically advanced areas and to understand the science behind these new approaches. The regulatory field must understand the critical quality attributes of these novel approaches and learn from each other's experience so that workforces can be trained to prepare for emerging global regulatory challenges. Moreover, it is essential that the regulatory community must work with the technology developers to harness collective capabilities towards developing a strategy for evaluation of these new and novel assessment tools.Entities:
Keywords: Emerging technologies; bioimaging; bioinformatics; biomarkers; regulatory science; risk assessment
Mesh:
Year: 2021 PMID: 34783606 PMCID: PMC8749227 DOI: 10.1177/15353702211052280
Source DB: PubMed Journal: Exp Biol Med (Maywood) ISSN: 1535-3699